Immunology | Preclinical Developments

Pandion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Pandion Therapeutics Presents Preclinical Data on Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease

Lead Product(s): PT001

Therapeutic Area: Immunology Product Name: PT001

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 22, 2021

Details:

The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes.

Imcyse

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: $180.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration February 03, 2021

Details:

Imcyse and Pfizer will collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis. Pfizer will lead clinical development and commercialization activities.

Slate Bio

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies

Lead Product(s): IL233

Therapeutic Area: Immunology Product Name: IL233

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Epidarex Capital

Deal Size: $1.7 million Upfront Cash: Undisclosed

Deal Type: Financing January 19, 2021

Details:

Financing will support development of novel IL-2 treatments for various diseases. IL233, Slate's lead candidate, is a first in class drug that induces persistent remission in animal models of autoimmune and inflammatory diseases.